Ser344
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser344  -  NFAT3 (human)

Site Information
QAVALPRsEEPASCN   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 11163859

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mass spectrometry ( 1 ) , mass spectrometry (in vitro) ( 2 ) , mutation of modification site ( 2 ) , western blotting ( 2 )
Relevant cell line - cell type - tissue:
HeLa (cervical) ( 1 ) , MEF (fibroblast) [RSK2 (human), homozygous knockout] ( 2 )

Upstream Regulation
Putative in vivo kinases:
RSK2 (human) ( 2 )
Kinases, in vitro:
RSK2 (human) ( 2 )

References 

1

Zhou J (2009) CST Curation Set: 7757; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

2

Cho YY, et al. (2007) RSK2 mediates muscle cell differentiation through regulation of NFAT3. J Biol Chem 282, 8380-92
17213202   Curated Info